EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

LSL Pharma Group Inc. (LSL) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of LSL Pharma Group Inc. C$0.05, price C$0.32, upside -84.4%, quality 13 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CA

LP Thin data Sep 23, 2026

LSL Pharma Group Inc.

LSL · V

Weakest SetupStrongly overvalued and low quality.

!Fair value C$0.0500 · Strongly overvalued (−84%)
!Quality 13/100
!Expensive Growth (revenue 5y +42.9 %/yr)
✓Solidly profitable · 10.4% net margin (TTM)
!Moderate debt · negative free cash flow
!Mixed vs. peers (5/11)
!Narrow moat 39/100
!Evidence only low, so the estimate is less certain
Watch LSL Pharma Group Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$0.9000 C$0.3000 Fair Value C$0.0500 Mar 2023 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

43‑month range C$0.3000 – C$0.9000 · fair‑value band C$0.0400 – C$0.0700 · the C$0.3200 price screens above the C$0.0500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow LSL Pharma Group in your weekly email

Every Wednesday you see whether LSL Pharma Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally.

Show more

LSL Pharma Group Inc. develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products in Canada, the United States, and internationally. The company offers dietary supplements and vitamins in the tablet and capsule form; niche sterile ophthalmic products in the form of ointments and drops; and cosmetic, pharmaceutical, and natural health products in liquid and semi-solid form for pharmacy banners and hospitals. The company is headquartered in Boucherville, Canada.

Stock analysis

LSL Pharma Group Inc. (LSL) currently trades at C$0.3200, while our model-based Fair Value estimate is C$0.0500, implying the stock looks roughly 540.2% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: C$0.0400 (bear) to C$0.0700 (bull), the price of C$0.3200 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 13/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

LSL Pharma Group Inc. reported revenue of C$28.7M in FY2025 versus C$8.8M in FY2021, a compound +34.5%/yr. Reported net income was −C$2.8M in FY2025.

Key figures

Market cap C$40.6M (≈ $28.7M) · P/S ratio 1.49 · EPS (TTM) C$−0.0400 · Net margin −9.8% · Return on equity 12.1% · Return on assets (EBIT) −8.1% · Operating margin 5.2% · Revenue (TTM) C$26.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 42% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −84%, LSL screens richer than that median.

Fair Value models

Bear C$0.0400 Fair Value C$0.0500 Bull C$0.0700
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) C$0.1100 C$0.1400 C$0.2100 54
All 1 models by family
Asset-Based
NCAV (Graham) C$0.1100 C$0.1400 C$0.2100 54

Open the full fair value analysis →

Notify me when LSL reaches fair value

Put LSL on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 13/100

Of which business quality 15 · Market factors (momentum, volatility) 34

Profitability 8
Margins and returns on capital today
Quality Growth 44
Are margins and returns improving?
Cashflow 8
Earnings quality: real cash, not paper profit
Fin. Strength 24
Balance sheet, leverage, solvency risk
Investment 5
Disciplined investing over empire-building
Low Volatility 61
Calm price path (market factor)
Momentum 27
Price trend over the last 3–12 months (market factor)
52W Momentum 13
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+62.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.9%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.8% (2020) → −8.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

LSL screens 540% overvalued. Compare with Merck KGaA →

Compare LSL Pharma Group Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks

Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 15 · Bottom 25%
Fair Value upside −84% · Bottom 25%
Profitability
Return on equity (TTM) 12% · Above median
Return on assets 2% · Below median
Net margin (TTM) 10% · Above median
Operating margin (TTM) 5% · Below median
Growth and dividend
Revenue growth 89% · Top 25%
Balance sheet
Debt / equity 0.99× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.06× · Cheaper than median
P/S (TTM) 1.07× · Cheaper than median
EV/EBITDA 14.4× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)100 · sector 20
PAST (return on equity)49 · sector 27
HEALTH (low debt)51 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.95 €108.70 −19%
Takeda Pharmaceutical Company TAK $18.81 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.01 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $71.61 $108.48 +51%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LSL Pharma Group Inc. · Fair Value
C$0.0500 −540%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "LSL Pharma Group Inc. Fair Value". https://www.fairvalue-calculator.com/stock/LSL

Frequently asked questions

Is LSL Pharma Group Inc. (LSL) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of C$0.0500 versus a price of C$0.3200, about −84% upside (overvalued).
What is the fair value of LSL?
Our model-based fair value for LSL Pharma Group Inc. is C$0.0500 (as of Sep 23, 2026), built from audited fundamentals. The current price: C$0.3200.
What is the quality score of LSL?
LSL Pharma Group Inc. has a Quality Score of 13/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LSL Pharma Group Inc. (LSL)?
Our model-based price target is the fair value of C$0.0500 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario C$0.0400, optimistic scenario C$0.0700. It is a calculation from audited fundamentals, not an analyst target.
What is the LSL Pharma Group Inc. stock forecast for 2026?
Our models put fair value at C$0.0500, about −84% upside versus a price of C$0.3200 (overvalued). Cautious scenario C$0.0400, optimistic scenario C$0.0700. The calculation is refreshed regularly with new filings.
What is the revenue of LSL Pharma Group Inc. (LSL)?
LSL Pharma Group Inc. reported trailing-twelve-month revenue of about C$26.8M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of LSL Pharma Group Inc. (LSL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LSL Pharma Group Inc. it is C$0.0500 per share (as of Sep 23, 2026), against a price of C$0.3200. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is LSL Pharma Group Inc. stock overvalued or undervalued in 2026?
As of Sep 23, 2026, LSL trades above its calculated fair value: price C$0.3200, fair value C$0.0500, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LSL?
No. The price is what the market pays today (C$0.3200); the fair value is what the company's own numbers justify (C$0.0500). For LSL Pharma Group Inc. the two are C$0.2700 per share apart. That gap is exactly why we show both numbers side by side.
How much is LSL Pharma Group Inc. worth?
The market values LSL Pharma Group Inc. at about C$40.6M (market capitalisation, as of Sep 23, 2026). Per share that is C$0.3200; our models calculate a fair value of C$0.0500 per share.
What do the bullish and bearish scenarios say about LSL?
Our models span a range for LSL Pharma Group Inc.: cautious scenario C$0.0400, base C$0.0500, optimistic C$0.0700 per share (as of Sep 23, 2026, price C$0.3200). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of LSL Pharma Group Inc. (LSL)?
Balance-sheet figures for LSL Pharma Group Inc. (as of Sep 23, 2026): return on equity 12.1%, debt of 0.99 per unit of equity. They feed the Quality Score of 13/100, which measures business quality independently of the share price.
How far is LSL from its 52-week high?
LSL Pharma Group Inc. trades at C$0.3200, about 42% below its 52-week high of C$0.5500 and 7% above the low of C$0.3000 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.0500 is for.
Which stocks are comparable to LSL Pharma Group Inc.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LSL Pharma Group Inc. stock attractive at the current price?
The data as of Sep 23, 2026: price C$0.3200, calculated fair value C$0.0500 (−84%), Quality Score 13/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LSL calculated?
We run LSL Pharma Group Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of C$0.0500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. LSL Pharma Group Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LSL Pharma Group Inc. (LSL)?
The closing price on Sep 24, 2026 was C$0.3200. Our model-based fair value is C$0.0500, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LSL Pharma Group Inc. right now?
The price sits above even our optimistic bull case (C$0.0700). The favourable scenario is already priced in. Weak quality (13/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of LSL Pharma Group Inc.

How large is the market capitalisation of LSL Pharma Group Inc. (LSL)?
The market capitalisation of LSL Pharma Group Inc. is C$40.6M (≈ $28.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LSL Pharma Group Inc. (LSL)?
The price-to-sales ratio of LSL Pharma Group Inc. is 1.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of LSL Pharma Group Inc. (LSL)?
Earnings per share at LSL Pharma Group Inc. are C$−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of LSL Pharma Group Inc. (LSL)?
The net margin of LSL Pharma Group Inc. is −9.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LSL Pharma Group Inc. (LSL)?
The return on equity (ROE) of LSL Pharma Group Inc. is 12.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LSL Pharma Group Inc. (LSL)?
On an EBIT basis the return on assets of LSL Pharma Group Inc. is −8.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LSL Pharma Group Inc. (LSL)?
The operating margin of LSL Pharma Group Inc. is 5.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LSL Pharma Group Inc. (LSL)?
Revenue at LSL Pharma Group Inc. is growing +89.0% versus a year earlier (3y avg +51.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does LSL Pharma Group Inc. (LSL) generate?
The free cash flow of LSL Pharma Group Inc. is −C$7.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does LSL Pharma Group Inc. (LSL) carry?
The net debt of LSL Pharma Group Inc. is C$29.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch LSL Pharma Group Inc. in the live analysis

One click puts LSL Pharma Group Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.